The pediatric study did show arbaclofen-associated broader measures improvement on several key secondary outcomes and a trend toward significance for arbaclofen on the primary endpoint, but the study was not adequately powered for the primary outcome measure due to early closure for financial reasons.
← all excerpts
Fragile X targeted pharmacotherapy: lessons learned and future directions.
1
—
—